How much weight do people lose on tirzepatide on average?

In SURMOUNT-1 (the registration trial for branded Zepbound published in NEJM 2022), participants on the highest 15mg dose lost an average of 20.2% of body weight at 72 weeks (about 17 months). The 10mg arm averaged 19.5% and the 5mg arm averaged 16.0%. Half of trial participants on the highest dose lost more than 22.5% of body weight; about 36% lost more than 25%. These are population averages — individual response varies substantially. Compounded tirzepatide does NOT have published trial data; the branded numbers should not be assumed to transfer directly.

How long does it take to see results on tirzepatide?

Most patients begin seeing weight loss within the first 4-8 weeks, but the most rapid loss typically occurs after dose escalation (months 3-6). The standard titration schedule starts at 2.5mg weekly for 4 weeks (a starter "tolerability" dose, not a full therapeutic dose), then increases to 5mg, 7.5mg, 10mg, 12.5mg, and 15mg in 4-week intervals if tolerated. SURMOUNT-1 measured at 72 weeks (~17 months) — that is the timeline at which the trial averages quoted in the literature were achieved.

Is the weight loss from compounded tirzepatide the same as branded Zepbound?

No data exists to confirm that. Compounded tirzepatide is produced by 503A pharmacies under FDA exemptions and does NOT undergo the same pre-market efficacy testing as branded Zepbound. The SURMOUNT-1 trial efficacy figures (20.2% average weight loss at 72 weeks) apply specifically to Eli Lilly's branded tirzepatide formulation. Compounded versions may produce comparable, lower, or variable results depending on batch quality, dose accuracy, and stability. Many patients report comparable subjective results, but no controlled head-to-head data has been published.

Why are some tirzepatide before-and-after photos online unrealistic?

Three reasons. First, photos shared online are self-selected — patients with dramatic results post; patients with average or below-average results often don't. Second, marketing photos may use lighting, posing, or compression to exaggerate visible change. Third, trial averages (20.2% on the highest dose at 72 weeks) describe POPULATION distributions — individual results vary from 0% to 30%+. We do not publish patient before-and-after photos for these reasons. Trial percentages are the honest reference point.

What should I expect realistically in my first 6 months on tirzepatide?

Realistic expectations from trial averages: Weeks 0-4 (2.5mg starter): 1-3% body weight loss, primarily from reduced appetite and water shifts. Weeks 5-12 (5mg, 7.5mg titration): 4-8% body weight loss as therapeutic dose is reached. Months 4-6 (10mg, 12.5mg): 9-14% body weight loss for typical responders. Side effects (nausea, GI symptoms) are most common during first 4-8 weeks of each dose escalation. Individual response varies dramatically; about 10-15% of trial participants had minimal response. Lifestyle (diet, sleep, activity) substantially modifies outcomes.

Tirzepatide Before & After — Trial Data + Realistic Timeline

The honest version: what published clinical trials show (SURMOUNT-1: 20.2% average weight loss at 72 weeks), how the timeline actually unfolds, and why compounded versions may not match branded trial data.

Updated May 5, 2026·By Chad Simpson

Why we don’t publish patient before-and-after photos

Three reasons. (1) Patient photos are self-selected — dramatic results post, average results don’t. (2) FDA and FTC guidance restricts specific weight-loss claims tied to individual patient outcomes, particularly for non-FDA-approved compounded versions. (3) Trial averages from published, peer-reviewed studies are the honest reference point — they describe population distributions, not cherry-picked individuals. Below: what the actual data shows.

TL;DR — Trial-Reported Average Weight Loss

SURMOUNT-1, 5mg/wk

16.0%

Average body weight loss at 72 weeks. Lower-dose arm. NEJM 2022.

SURMOUNT-1, 10mg/wk

19.5%

Average body weight loss at 72 weeks. Mid-dose arm. NEJM 2022.

SURMOUNT-1, 15mg/wk

20.2%

Average body weight loss at 72 weeks. Highest-dose arm — about 50% more than semaglutide head-to-head. NEJM 2022.

Source: SURMOUNT-1 (NEJM 2022). Branded tirzepatide (Zepbound). Population averages across 2,539 adults with obesity or overweight + comorbidity. Individual results varied — about 10-15% of participants had minimal response.

Realistic Month-by-Month Timeline

Tirzepatide follows a standard titration schedule — the dose increases every 4 weeks if tolerated. The starter dose (2.5mg) is a tolerability dose, not a full therapeutic dose. Most weight loss occurs after the dose reaches 7.5–15mg. Here’s the typical trajectory based on SURMOUNT-1 data and the standard dose-escalation protocol:

Month 1 (Weeks 1-4)

2.5mg weekly

1–3% body weight loss

Tolerability dose. Side effects (nausea, fatigue, GI) most common. Appetite reduction begins. Water-weight shifts can produce visible scale change disproportionate to fat loss.

Month 2 (Weeks 5-8)

5mg weekly

3–5% body weight loss (cumulative)

First therapeutic dose. Appetite suppression typically more pronounced. Side effects often improve as body adjusts. Weight loss may slow if dose escalation is delayed.

Month 3 (Weeks 9-12)

7.5mg weekly

5–8% body weight loss (cumulative)

Steady-state therapeutic dose for many patients. Some patients see plateau and remain at this dose long-term if response is sufficient.

Month 4 (Weeks 13-16)

10mg weekly

8–11% body weight loss (cumulative)

Standard escalation if response at 7.5mg is insufficient. Clinical trials show 10mg arm averaging 19.5% at 72 weeks — most rapid weight loss occurs in months 4-6.

Month 5 (Weeks 17-20)

12.5mg weekly

11–14% body weight loss (cumulative)

Higher therapeutic dose for patients who require more aggressive titration. Side effects may re-emerge briefly during dose change.

Month 6 (Weeks 21-24)

15mg weekly (max)

12–17% body weight loss (cumulative)

Maximum approved dose. Most patients who reach this dose continue through month 12+ to capture the full SURMOUNT-1 trajectory.

Months 7-18 (long-term)

Maintenance dose

15–22% body weight loss (cumulative average)

SURMOUNT-1 measured at 72 weeks (~17 months). Highest-dose arm averaged 20.2% at this endpoint. Weight loss slows but typically continues through month 18; plateau is common at month 24+.

Timeline reflects standard titration on branded Zepbound. Compounded tirzepatide may follow different titration protocols depending on prescriber and provider. Individual response varies substantially — these ranges describe trial averages, not guarantees. Lifestyle, baseline weight, and adherence all modify outcomes.

How Results Were Distributed in SURMOUNT-1

The 20.2% average weight loss number obscures meaningful variation. SURMOUNT-1 reported the proportion of participants who reached different weight-loss thresholds at 72 weeks on the 15mg dose:

Weight Loss Threshold	15mg Tirzepatide	Placebo (Trial Comparator)
≥ 5% body weight loss	91%	35%
≥ 10% body weight loss	84%	19%
≥ 15% body weight loss	71%	9%
≥ 20% body weight loss	57%	3%
≥ 25% body weight loss	36%	1.5%

Source: SURMOUNT-1 (NEJM 2022). Numbers represent percentages of trial participants reaching each threshold at 72 weeks. Approximately 9% of 15mg participants did not reach the 5% threshold — minimal response is real and not uncommon.

What Substantially Modifies Your Result

Why two patients on identical 15mg protocols can have wildly different outcomes:

Lifestyle (diet, activity, sleep)

Tirzepatide reduces appetite — patients who pair it with even modest dietary adjustments and activity tend to capture the higher percentile of trial outcomes. Patients who increase intake to "make up" for reduced appetite (a real pattern) tend to underperform trial averages.

Adherence to dose schedule

SURMOUNT-1 results assume consistent weekly dosing through 72 weeks. Missed doses, delayed escalations, or treatment gaps reduce cumulative weight loss. Some patients pause for side effects then never resume — these patients show below-average results.

Baseline weight and body composition

Higher baseline BMI patients tend to lose more absolute weight; relative percentage loss varies. Patients with higher muscle-mass ratio tend to preserve more muscle (with adequate protein intake) and lose more fat selectively.

Compounded vs branded

Branded Zepbound has standardized dosing and FDA-approved manufacturing. Compounded versions may have batch-to-batch variability in concentration, purity, and stability. Reputable LegitScript-accredited 503A pharmacies minimize this; lower-tier providers do not. Post-April 2026 FDA enforcement narrowed the 503A landscape — see our compounded tirzepatide guide for the regulatory deep-dive.

Stopping the medication

Roughly two-thirds of weight lost on tirzepatide is regained within 1-2 years of stopping, per the SURMOUNT-4 maintenance trial. Most prescribers consider tirzepatide a long-term metabolic treatment, not a short-term weight-loss aid.

The Honest Read on Compounded Tirzepatide Results

Most affordable tirzepatide programs marketed online ($179-$399/mo at telehealth providers) are compounded tirzepatide, not branded Zepbound. The SURMOUNT-1 efficacy data described above applies specifically to branded Zepbound from Eli Lilly — not to compounded versions produced by 503A pharmacies.

What we know: The active molecule (tirzepatide) is the same. The mechanism (dual GIP + GLP-1 receptor agonism) is the same.

What we don’t know: Whether the compounded formulation matches branded Zepbound’s bioavailability, potency, and stability. No published head-to-head clinical trial has compared compounded vs branded tirzepatide weight-loss outcomes. Reputable 503A pharmacies follow USP standards and produce consistent product, but the FDA does not validate this on a per-batch basis the way it does for FDA-approved drugs.

What patients report: Many patients on compounded tirzepatide report subjective results comparable to expectations from trial data. Some report less response than expected. The signal in patient communities is positive on average but variable.

Practical implication: Treat the SURMOUNT-1 numbers as a reasonable upper-bound expectation. Some compounded patients will match the trial averages; some will see less. The post-April 2026 FDA enforcement environment has narrowed which 503A pharmacies are still operating for routine telehealth-scale tirzepatide compounding — verifying your provider’s compliance status and pharmacy accreditation (LegitScript, NABP) is more important than ever.

See our full compounded tirzepatide guide for the regulatory landscape and verified provider stack.

Verified Compounded Tirzepatide Programs (May 2026)

All providers ship to all 50 US states. Pricing verified May 5, 2026.

Top Compounded Tirzepatide Providers

Pricing accurate as of May 2026. Click a provider to see current pricing and start a consultation. We may earn a commission — at no extra cost to you. See our affiliate disclosure.

Provider	Monthly Price	Medication Types	Rating	Action
SkinnyRxBest Overall 503A compounded GLP-1 specialistCompounded Tirzepatide + Semaglutide (503A pharmacy)	$199–$399	Compounded Tirzepatide + Semaglutide (503A pharmacy)	★★★★★4.9	View Best Offer
TrimRx Online weight loss program with GLP-1 medicationGLP-1 weight loss program (catalog VERIFY)	From $179/mo	GLP-1 weight loss program (catalog VERIFY)	★★★★☆4.5	View Best Offer
MEDViEditor’s Pick Reliable mid-tier compounded GLP-1Compounded Tirzepatide + Semaglutide	$179–$299	Compounded Tirzepatide + Semaglutide	★★★★☆4.6	View Best Offer
DirectMedsBest for Sublingual Sublingual + injectable compounded GLP-1Compounded Sema + Tirz (injectable + sublingual), Sermorelin, NAD+, Epithalon	$179–$399	Compounded Sema + Tirz (injectable + sublingual), Sermorelin, NAD+, Epithalon	★★★★☆4.5	View Best Offer
Ivim HealthBest for Microdosing 360 wellness — branded + compounded + microdosing GLP-1Compounded Sema/Tirz/Liraglutide, microdosing GLP-1, Wegovy/Zepbound/Mounjaro/Ozempic/Saxenda, Wegovy Pill	From $75/mo + $74.99 program fee	Compounded Sema/Tirz/Liraglutide, microdosing GLP-1, Wegovy/Zepbound/Mounjaro/Ozempic/Saxenda, Wegovy Pill	★★★★☆4.7	View Best Offer
Eden HealthBest Value Branded + compounded with intro pricingCompounded Sema + Tirz, branded GLP-1, NAD+ (5 formats), Sermorelin, hormone therapy	$149 intro / $229–$249 ongoing	Compounded Sema + Tirz, branded GLP-1, NAD+ (5 formats), Sermorelin, hormone therapy	★★★★☆4.7	View Best Offer

Pricing and availability current as of May 2026. We earn a commission if you sign up through our links — at no additional cost to you. See our methodology for how we evaluate providers.

Realistic First-Month Setup (For New Patients)

Weeks 1-2 — Adjustment

Reduced appetite typically begins within 2-3 days of first injection
Early side effects: mild nausea, fatigue, GI changes (constipation or diarrhea)
Hydration matters substantially during weeks 1-4 (low intake amplifies side effects)
Scale change in week 1 is usually water shifts, not fat loss

Weeks 3-4 — Stabilization